This reduction can in turn lessen the ability of the intestine to heal itself, making it more prone to inflammation and cancer initiation [28–33], thus suggesting PRL-3 as a new therapeutic opportunity for cancer prevention by inhibiting it at the stage of (chronic) inflammation. This evidence concerns the gene PTP4A3 and cancer.